Evidence map›Paper›PMID 26808566›Full record

ArticleBone marrow transplantation2016

Comparable outcomes between autologous and allogeneic transplant for adult acute myeloid leukemia in first CR.

M Mizutani, M Hara, H Fujita, J Aoki, H Kanamori, K Ohashi, K Usuki, T Fukuda, T Chou, J Tanaka and 2 more

Abstract readComparative Study
PubMed Publisher
In one paragraph

Article in Bone marrow transplantation, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
25citing papers in PubMed, 2 pooled it
3.9field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

25 citing papers in PubMed, 2 syntheses or guidelines pooled it, 49 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Article
  5. Article
  6. Article
  7. Article
  8. What Influences the Decision to Proceed to Transplant for Patients With AML in First Remission?Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2023
    Review
  9. Review
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Review
  17. Article
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 9 institutions in 1 country.

M MizutaniDivision of Hematology, Department of Internal Medicine, Aichi Medical University School of Medicine, Nagakute, Japan.
M HaraDepartment of Medical Innovation, Osaka University Hospital, Osaka, Japan.
H FujitaDepartment of Hematology, Saiseikai Yokohama Nanbu Hospital, Yokohama, Japan.
J AokiDepartment of Hematology, Kanagawa Cancer Center, Yokohama, Japan.
H KanamoriDepartment of Hematology, Kanagawa Cancer Center, Yokohama, Japan.
K OhashiHematology Division, Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital, Tokyo, Japan.
K UsukiDepartment of Hematology, NTT Medical Center Tokyo, Tokyo, Japan.
T FukudaDivision of Hematopoietic Stem Cell Transplantation, National Cancer Center Hospital, Tokyo, Japan.
T ChouDepartment of Internal Medicine, Niigata Cancer Center Hospital, Niigata, Japan.
J TanakaDepartment of Hematology, Tokyo Women's Medical University, Tokyo, Japan.
Y AtsutaJapanese Data Center for Hematopoietic Cell Transplantation, Nagoya, Japan.
A TakamiDivision of Hematology, Department of Internal Medicine, Aichi Medical University School of Medicine, Nagakute, Japan.
Aichi Medical University · JPKanagawa Cancer CenterNagoya University · JPNiigata Cancer Center Hospital · JPNTT Medical Center · JPOsaka University Hospital · JPSaiseikai Ibaraki Hospital · JPTokyo Metropolitan Komagome Hospital · JPTokyo Women's Medical University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Although allogeneic hematopoietic stem cell transplantation from an HLA-matched sibling donor (MSD) is a potentially curative post-remission treatment for adults with acute myeloid leukemia (AML) in their first CR, transplant-related morbidity and mortality remains a major drawback. We retrospectively compared the outcomes of patients who underwent autologous peripheral blood stem cell transplantation (auto-PBSCT; n=375) with those who underwent allogeneic bone marrow transplantation (allo-BMT; n=521) and allo-PBSCT (n=380) from MSDs for adults with AML/CR1, in which propensity score models were used to adjust selection biases among patients, primary physicians and institutions to overcome ambiguity in the patients' background information. Both the multivariate analysis and propensity score models indicated that the leukemia-free survival rate of auto-PBSCT was not significantly different from that of allo-BMT (hazard ratio (HR), 1.23; 95% confidence interval (CI), 0.92 to 1.66; P=0.16) and allo-PBSCT (HR, 1.13; 95% CI, 0.85-1.51; P=0.40). The current results suggest that auto-PBSCT remains a promising alternative treatment for patients with AML/CR1 in the absence of an available MSD.

Indexed as

AdolescentAdultAgedAged, 80 and overBone Marrow TransplantationDisease-Free SurvivalFemaleHumansLeukemia, Myeloid, AcuteMaleMiddle AgedPeripheral Blood Stem Cell TransplantationPropensity ScoreRemission InductionRetrospective StudiesTransplantation, Autologous

Identifiers

PMID26808566
OpenAlexW2272195922

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.